Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | RPA1 | P27694 | 8/20 | 0.62 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | MARS1 | P56192 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987609 | 0.86 | RPA1 (0.82) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL5474891 | 0.85 | PTGS2 (0.54) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL16876788 | 0.84 | RPA1 (0.58) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL16876800 | 0.83 | MEN1 (0.60) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL9210302 | 0.82 | RPA1 (0.57) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL16876850 | 0.82 | MEN1 (0.58) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL5483244 | 0.80 | TAAR1 (0.50) | MEN1KMT2ASMN1; SMN2MARS1 | |
| SCHEMBL27714729 | 0.80 | KMT2A (0.89) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL16876785 | 0.80 | MARS1 (0.57) | MEN1KMT2ARPA1PPP1CAL3MBTL1 | |
| SCHEMBL954786 | 0.79 | KMT2A (0.50) | MEN1KMT2ARPA1PPP1CAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225335-A1 | Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
| CN-101001626-A | Pyrazole derivatives for treating conditions mediated by activation of the adenosine A2b or A3 receptor | NOVARTIS AG (CH) | 2007-07-18 | — | — | CN | disclosed |
| EP-1799206-A2 | PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR | Novartis AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006015860-A2 | PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225335-A1 | Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor | ADORA3, ADORA2B, ADORA1 | MEN1 4248/4885KMT2A 1160/4885RPA1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.